- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello and thank you for standing by. Welcome to the G1 Therapeutics Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. to President conference of like opening to now Vice speaker, Communications, would hand over the your I Will Roberts. proceed. please Will,

Will Roberts

Thank regimen of business an was update. and approved issued and administered everyone, press that Q&A session release call and third Good financial remarks. in the our The XXXX of in Sheena. Sheena the platinum topotecan results small incidence these to quarter a update team this is to period can stage in extensive found corporate available myelosuppression follow etoposide including on when be the decrease clinical morning and a will containing conference our to as our A morning's provide our lung welcome On for results prior financial cancer quarter ES-SCL. gXtherapeutics.com. this prepared the website commercial patients the commercially cell business which overview of on and continue XXXX, GX call, or programs discuss you, said News will the to or morning, with regimen third COSELA, chemotherapy-induced section of progress adult a

actual like involve statements certain begin, of risks and the may to to that I or that contains statements materially you results represent cause implied forward-looking differ expressed Such these XXXX. in I'd statements. Before Securities Litigation webcast of by as within and today today's of meaning from Act the remind Private Reform management's those could judgment uncertainties

corporate Any November of are or Securities views our on with please forward-looking and Commission, more statements available refer today, which website. such our represent information to the uncertainties, SEC XXXX. and the on from X, filings For Exchange risks as our

our our Jack? call the Moses, Andrew Medical Officer; Officer; Financial Malik, turn the to our Chief today our Jack. Officer. on over Raj call and now me Chief are Jen Commercial Chief I'll Executive Perry, Bailey, Officer; Chief Jack Joining

Jack Bailey

you joining call today. Thank for everyone. us the Good morning, on

During COSELA additional quarter, opening we continued execution quarter. topics. will achieved demonstrated to experienced clinical Raj comments lower momentum color on my sales what both second then the provide and we our Andrew also and in cover the each third both versus I'll program, but in

proud First, of progress team the clinical I'm the achieved.

related discuss morning clinical R&D that X the ADC provide that myelosuppression, initial will compared safety its the published that meaningful govitecan Raj diarrhea, adverse announced reductions milestones sacituzumab our we reached our such from quarter, this safety of in potentially clinically to seeing as and during even are events ADC. As of in shows with among we've this single sacituzumab we to potential alopecia profile since September, agent Day results and over XX% encouraging trial Phase previously to

trial X We negative call trilaciclib cancer also our triple and in bladder breast discussed metastatic Mechanism X and for trial. trial enrollment Action our Phase our as last the of we cancer Phase completed in

have been of for Next, Symposium effect presentation X our the in San additional on accepted accepted presentation MOA Cancer November. the trial Cancer for abstracts Antonio Breast non-clinical for trilaciclib's potential Society data providing have been meeting meeting. Immunotherapy results at Two Phase anti-tumor at

the in Finally, expecting. that remain pivotal in are results deliver we breast results initial At our our Phase cognizant sales same and most triple for we cancer of X were timelines level of time, of did perhaps that intact colorectal we fact not importance trials cancer. and for the negative the

from balanced increase patient on by account year. new reorders Andrew, a are in As flow, variability Though, through existing working different and to you'll this staffing, market additions XX% hear at organizational the due pressure times from accounts. we some of was

professionals to them reactively. or as small remain as months. the We time and proactively hematologic the putting will We first of initial underscore confident patients is that over as a the from healthcare describe in extensive Andrew cancer will ADC provides. changing side benefit COSELA chemotherapy experienced in today for potential the treating every from reduce a than prevent COSELA drive enables multi-lineage It's drug that growth effects that have actions that paradigm are oncologists place who the the coming lung rather trial our ever. start. of unique We day of only the And cell results stage variety hear serious just

ask quarter, like since XXXX. an during first value months, cancer. of then coming will in will first our during initial this potential Since on efforts to I We with marks new over including are convinced Day, actions much commercial Andrew of many clinical ADC provide markets safety overview our R&D an overview our starting cover field the of results. update the the morning, the an colorectal team results, of the momentum quarter the and Raj disclosures its recent of and bigger sales third our of data clinical

provide I'll results will the quarter be financial Finally, to the I'll back Jen Raj. With call and comments. concluding some over the for turn for that,

Raj Malik

with In data to Jack, discussed topics timing to the of XXXX what of therapies. all govitecan will Phase sacituzumab start we morning, for those anti-cancer expect other the including announced triple morning. from fronts safety results initial to with in good initial everyone. cancer our and We've on new breast supporting variety trilaciclib made and September, held since we negative a progress with this trilaciclib Thanks, good the results patients and preclinical that then. and encouraging R&D X I potential synergistically work results Day

of numerous when the is ADC present relative agent these sacituzumab precluded fall, at that. submission to prior single safety the this well by with abstract govitecan. data this had administered to seeing small of sacituzumab trilaciclib published hoped to over a the previously adverse conference are in time the We medical We consistent of XX% at profile rates associated numbers events but reductions summer

data and the Though in trends of safety to study. key adverse in emergent enrollment the the time been treatment recent consistent been over monitoring the results the XX patients' events have to-date. momentum XX safety However, the evaluate first unaudited early opportunity we have of provided enrolled the

these of these Specifically, X which Grade to dropped reductions of neutropenia, are grade potentially data alopecia. of from XX% from with The to sacituzumab, sacituzumab anemia, and presence This some of the XX% any to rate rate which trilaciclib in crypt X% in rate and of the the related the and likely of the the hair the due but XX% intestinal and in X the is in of reduction in expected myelosuppression dropped follicles. rates data rate in examples expressing which XX% the Though and cells also CDKX/X in diarrhea sacituzumab. from we the trilaciclib encouraged XX% to ADC on-target of the combination to results trilaciclib, indications. data. occurrences by mature, X to to dropped potential with sacituzumab Grade and investigators not will We in and any only sacituzumab across reviewed with the have grade effects begin of very these on-target diarrhea, trilaciclib XX% with such no continue as view in for as sacituzumab diarrhea they early who clarify data other are govitecan are as the because

irinotecan. could in We our safety XXXX. data In read quarter of regimen at through includes study, FOLFOXIRI medical the also and comprehensive which colorectal in addition, more presenting to the the efficacy a meeting look data forward to second these

on Next, pivotal Phase X trials. our I'll comment

and colorectal the effect Grade of patient XXX endpoints of assessments severe as trilaciclib duration of trial trilaciclib of cancer, in measured PRESERVE induction line compared in first X, primary First of neutropenia on with during one are by through X the or our in myelosuppression cycles occurrence metastatic neutropenia four. placebo the severe

for patients FOLFOXIRI. first read pivotal the and quarter limiting If myeloprotection to release cancer trial. is other a trilaciclib in approval We discuss this positive, which like of colorectal in the be expect dose diarrhea, XXXX myeloprotection effects to This authorities regulatory data indication. of meet we with on-target results will on out can in receiving filing

we in line cancer X, or first trilaciclib gemcitabine positive with negative PRESERVE tumors carboplatin. in placebo pivotal triple trial prior Next, receiving and completed and line patients enrollment negative PD-LX breast our to XXX recently first

in rule, we our report top-line overall the to of will the second the meets does will continue analysis. data final interim monitoring analysis and the committee results. it If expect be to will not, year. conducted trial survival the interim trial the half it analysis If stopping by terminate the We next

shift let's ongoing other on progress to X Next, Phase trials.

action As least completed survival overall we said trilaciclib, we on PRESERVE effects of to during in enrollment response expect We like of the recently on see rate. R&D greatest the mechanism X. survival, the Day, and effect on endpoints based efficacy and longer-term progression-free

primary endpoint of tumor followed Our Phase safety inhibitor avelumab checkpoint progression-free chemotherapy in in with the by survival XX Initial quarter X bladder combination fourth in and response with the trial year, data are the expected cancer. on in data immune this and patients XXXX. trilaciclib of of

this to of said, not in have do we the result we trial a likely expect As myeloprotection backbone. gemcitabine as containing see

the Phase describe will abstract results accepted Antonio the immune our initial San December. on was the Antonio action Symposium The of presentation initial Breast results. San the for poster at Next, Cancer upcoming endpoint poster trial X of in mechanism

to complete Additional enhancing the the other for long-term immune T-cell immune cycle and data activation we improving cancer enhance microenvironment response data in expected data, describing are altering surveillance. preclinical trilaciclib XXXX. September, and including pathological potential new tumor by discuss and profiling In the favorably immunity

good been Annual the accepted Meeting. summary, mentioned, positions two at work have Jack made period. we well As In XXXX rich recent progress a data and this have for we abstracts it believe us on for SITC presentation

real recently on shows chemotherapy population will the supportive Summit stage COSELA Andrew have this turn in of mention utilization, With demonstrate In the over real that COSELA used reductions practice, a myelosuppression, potential cancer cell heterogeneity, presented world overview. for COSELA new needs. that, Precision is Andrew? world continue heterogeneous hematologic reduce adverse Finally, the dose consistently at patients. commercial a we supportive impact Despite that events to I'll I and occurrence care Oncology can of and the lung to that care severe call also small and extensive delay. the to data

Andrew Perry

third with on to factors and a we're topics, effecting of provide I'm in of an putting Raj. Thank number growth be sales glad drive some place the going you performance, you, that a today description forward. commercial of actions growth update to will including quarter

co-promotion managers complete by early of agreement Ingelheim our solely quarter COSELA own was GX the March. which third was with termination during in promoted second period our Boehringer account our The of oncology sales following team

ended representing year last quarter we volumes was in net COSELA QX. have the quarter progress we with activity, with demonstrating approximately Our with demonstrate $X.X QX. XXX% of flat platform compared overall same compared vial growth, We as sales QX with Volume sales with million goal made growth volumes build execution. quarter sales discuss the similar Beginning I'll affecting and QX, some in on the today. in of factors volume generated delivered which and growth this was to in we of the

the at As market the reviewed we in of you cell cancer growth flow the due claims, we the approximately with lung patient patients new recall, we quarterly in at of remarked QX, but XX% declined when We've can of times small those patient two first small QX. lung showed of cancer on state that most year. different months might with compared QX compared recent year this variable to number be healthcare pressure of XX% cell staffing available from that month-to-month and organizations results, the reporting estimate level extensive QX and around

new accounts reminder, accounts added for small existing in lung off year, cancer growth fewer a who their stage in and reliant last As is accounts market, QX QX. gaining we in than from highly the drop Similar to to regimen our cell compensate patients new quarter complete quarterly chemotherapy order patients new therapy. or in from in either same extensive

the of of around had However, accounts increased we existing volume from by reordered vials XX%.

XXX, added organizations total end COSELA seven of ordered launched us new top of which since the giving also XXX top of QX, to-date. the XX have We a

centers academic in volume of our a in estimate an the X% first our We share this the clinics come of in XX% and our in uptick provided our the QX academic through of X% commercial supply in with majority COSELA to from demand program. overall was result, quarter. line XX% through representing in in and community volume XX% saw As hospitals, of use. actually quarter patient volume centers the of nearly quarter market, increased patient represents assistance which

new was driven numbers diminished the cell which of new fewer extensive added, small resulted COSELA patients in our QX together and performance accounts fewer market, in patients. stage new So by

was reorders more this existing balanced and However, accounts. by depth of

to intention industry third-party as compose Our of the calls paramedic dose with QX, effectiveness awareness majority covered stable to sales strong. to Medicare remains high continue remained COSELA norms. sales remained force the among by exceed engagements oncologists reimbursement oncology face-to-face and our majority prescribe, continue in brand has measures and of

several deliver beginning growth We introduced new negotiations with community in these oncology oncologists QX. anticipate XXX with outcomes, trial on first Board, sales marketing entered for and organizations to networks are quarter. claims Looking considering large finalized. QX, adoption. new patient sales execution for see moving reason to come opportunities QX; of incentive that of quickly recently managers ensure provider including initial many incentivized reviewing already highly into impact the territory we We We several with level having forward, introduced a top only In account in further so advocacy improving all time the in are which believe then the agreements into are becomes our pivotal COSELA. goals for volume-based to for reported we one

We since launching speaker completed our expanded and speaker first training recently also bureau COSELA. live our

made including Overall, the we in of quarter we one changes patients. operational quarter territory and despite some sustained prior challenges execution in realignment new resulting where was some of this XX territory making a Finally, demonstrated in flow the fewer high-levels total.

XXX Going patient experience. of XX in over variability have forward, flow, now accounts although the organizations and top COSELA we anticipate with some XXX in month-to-month total we well

are Jen the the Our stage experiences are of patients have in new our financial for and places position to they with opportunity ready resources, believe update. peers. many to volume-based and believe marketing in we that those benefits we're Together ensure network share select customers This strong well-positioned level a with strongly when patient-focused moving I'll their us receive their patients over growth turn the Jen? for extensive territory more to diagnosed, COSELA contracts, COSELA. stronger for incentives, that, new sales to With provider a forward. call

Jen Moses

Thanks, Andrew, good morning, and everyone.

of the XX-Q, market morning's results after XXXX full to in which close. mentioned, available and we the intend Will are financial quarter for release As third press this be in will file

of total revenue the third comprised $XX.X $XX.X of quarter million license for million and $X.X revenue COSELA Our XXXX of was revenue of million. net

million of same goods approval revenue related the China. million development $X.X XX, in sincere related was revenue and license total license September included revenue $X.X to period $X.X three in including is For revenue. compared $X.X milestone quarter in $X.X sold of for period the product COSELA months XXXX. agreement primarily from and net revenue million milestones $XX the XXXX, for recognized license the to related million XXXX, was to current ended two payment COSELA The million same a million the of Cost of to for the from

million decrease and the due support for to a XXXX of expenses pharmaceutical to primarily product research of compared expenses quarter XXXX. was ingredients active the $XX.X The third clinical for were development in to decrease Our $XX.X for in quarter drug trials. manufacturing cost and million R&D third

to we third costs, to administrative quarter $XX.X personnel $XX.X by medical technology in in commercialization XXXX. two the of and compared million periods, Comparing general professional and selling, saw for costs. for due offset administrative costs increases were and of million the Our increased quarter headcounts third and expenses spend, decrease costs XXXX affairs the

XXXX. million million our in December XX, securities the release $XXX position equivalents $XXX.X morning, as quarter cash, cash and to of the Regarding cash described third marketable this we of as compared press with ended

have some the over our are amended to extended the I'll comments. Jack Jack? able flexibility that, have into to provide covenants We draw available to the agreement $XX With June with to call closing with we XXXX. million additional for back of our Hercules turn us and timeline

Jack Bailey

your day. cancer Raj, always, thank to Will. team people and GX the Thank want with I goals you drive for And our living toward you, Andrew, every inspiration, as Jen,

to you Before of that to I today. have we Q&A, just heard move want recap some the points

numerous related results and We myelosuppression, ADC very initial clinically to are XX% that even trial its Phase over of safety as adverse encouraged potentially such by alopecia. reductions in potential diarrhea, show X events well our sacituzumab the provide meaningful to from sacituzumab,

existing first data will this from the to and Antonio the we offset with from of growth in was in achieved variability the pivotal reordering. MOA the press COSELA versus provide networks. We've in reported Phase several fewer trials results our why in sales our be starting patient data year. we issued experienced XXXX, provider expect on Board will with quarter, via coming at two next agreements double-digit cancer by patient lower during new TNBC initiated marketing and level We trials second quarter, sales accounts CRC in year, quarter release. addition including initial two already large due and ongoing accounts largely X additional CRC presented data be what flow outcomes this to actions and and later territory The materials, momentum of bladder San We volume-based saw the incentives, and

We months. coming drive the over are stronger confident will that this COSELA growth

want Given I the momentum, on the comment XXXX. lower expectation our of COSELA remainder for sales to do

we your put and actions soon provide I to these the drive and in rollout, performance we expect have through as initiatives as in will rate that an be time confident intend feel into that on we Thank effective and said, COSELA the place have growth in quarter, XXXX. of growth as they update we as quarter that and to XXXX anticipate We impact. formal head fourth will over we we guidance As the this you drive third morning. we for

in and close ask with how Q&A. that, Operator a the please continuing quarter XXXX heard meetings opportunities turn it data initial throughout the format call. from trial you I'll Phase And communicate at our this have of question. starting fourth today, would call on speak and X our to to X full-year as to regarding and this remind will variety you you've again listeners quarter the We XXXX. we'll later over Phase medical With and

Operator

this [Operator Yes. will time, you. Thank we At the session. question-and-answer conduct Instructions].

Okay.

from Gil line Company. is open. from Needham of & question first our comes So your line the Gil,

Gil Blum

Hi, everyone, questions. thanks taking good morning, and for our

So here? of I seasonal disease. I've Can maybe therapy immediately. you the and lung dynamics of small explain mean kind on one go maybe a thought first never for pretty cell Andrew. as cancer a aggressive usually patients

Andrew Perry

Yes. agree you. I Thanks, with mean Gil. No, I

obviously quickly. I think very once can progress patients diagnosed,

the that promote I for times healthcare find, the QX different at the think true a picking extensive process that it's in I decline a during do though of for patients hear look that well. receiving those past likely in presentation was are the And QX. is of of we of bit diagnosis there then, in are get stage diagnoses, providers staff that We in available that and data of that a there more XX% we course, year. lead of a to period harder just up those from kind said to born to that as so symptoms of patient around product in claims far is as therapy data, that healthcare new any hold did

a really it's combination patients that external led going on factors QX. to COSELA new in of So fewer those

Gil Blum

And helpful. couple a that's questions Then Okay. for Raj.

does First with reduced one, significance and that may specific found? you context lead in -- tested amount AEs treatment? reducing will ADC can talks the you Do think of to put lead the usually the be to talks was of

Raj Malik

was greater between then to should so in of at a of greater and myeloprotection Gil. Trodelvy. this Trodelvy ASCO, what presented certainly which allow Hey, right? a that actually paper will exposure, looking Yes, relationship tolerability allow study, response. that's better which So There exposure good showed we're for efficacy

study. behind that So conducting the the exactly rationale is

far. by we're perspective encouraged so a we're what seeing from safety So

Gil Blum

last Okay. And maybe a one.

mean chemo? you've of dose additional briefly, there across talks which and common So toxicity is evidence, COSELA very mentioned limiting the a I activity gut-related diarrhea is gut the in

Raj Malik

replication. following We've showed stem-like Yes, for are that which that ourselves. induced done is a inhibitor intestinal in There we've that that's been radiation that CDKX/X using And crypt cells toxicity. a something the X/X actually upon some dependent work the the reduce was actually. gut hypothesis published paper can

similar protective marrow as gut that could the we the bone So the well. in see in mechanism apply

you know, of as causes obviously diarrhea. I is a lot think SNXX,

in early SNXX is it's the course that signs And that which we of know, And there. out rise so to the the we're encouraged remarks FOLFOXIRI gives as pointed and part also regimen in also my is regimen. that causes of diarrhea parent you irinotecan, by drug

So also. we'll happens the what to diarrhea be trial evaluate very to interested in colorectal

Gil Blum

the Thank on questions for taking right. luck of year. the you our good and All rest

Jack Bailey

Thanks, Gil. Operator?

Operator

question. Please standby Oh. the next for

next question from Dane, from comes Our your is open. line Dane RJF.

Dane Leone

taking Hey, thanks the for questions.

today On and therapy and patients median in trilaciclib to compares compares rate for that could context the initial provide the were of cohort? median, had of cycles that more to the getting in for ahead six XX of that that of the the results that those agency-based terms cycles how were How they that therapy study. you received Trodelvy, actually study those the patients response to seven or in some sharing combination of I guess SN sorry, number cycles that they the getting of or maybe you're SN four

the I is just of understanding we're study. some think the those today would've gotten for exposure of comparable context whether what in comparing have looking presented the in you. that is that Thank you within table patients AE drug way

Raj Malik

Raj responses all. study, the Dane, Hey, in terms seen of so first here. we've Yes. of responses, Yes, in

part the mentioned, of slow. the early As enrollment pretty study actually was the in I

patient was The safety. to some have enrolled in long-term we first data evaluate January, so do

of have come the However, the three say on plus actually the in months. bulk last patients

It's was But the early really goal to we've clearly, if enough data. still extending the do those and seeing to important toxicities to improvement as really it's make early to responses responses, you of Trodelvy really anticipate patients out action. of make therapy neutropenia PFS. happen a Gil on, that reason longer-term as us events an on to you that So not us these don't why such also duration enough for be. and potentially allow as to the on more we based on thought ultimately only that know, mechanism as rate like true is of asked response could put was what assessment. the received And although as the in it know, before, cycles But assessment diarrhea mentioned extend improve and we

Dane Leone

Sorry, follow-up that just safety valuable the terms included in that. of to for dataset, exposure to that including patients the XX for used and What in you cohort the sacituzumab the govitecan? was what -- in Thank were on you preliminary them you. criteria

Raj Malik

Patients yes, Yes. to one therapy. the of have have certainly completed trial cycle at on plus And received it least up combination sacituzumab.

Dane Leone

have have -- you Do cycle breakdown of of how AE a break yes, that Do patients in yes? many you one table a were more -- than included are had sacituzumab? that

Raj Malik

vast majority actually more Yes, had one. the than have

Dane Leone

They you AE which disclose want comparable And for trying are cross you're is can't then validates AE Okay. make ORR AE think comparison the that people really to better. don't it's what this sure for I that to looking table, the the you be for make. that cohort. -- just to

Raj Malik

though and exposure happen there Yes, significant a number some safety an Trodelvy from are difference we've of between in -- responses that There early from from assessment Dane. think happen even assessment Yes, like the as cycle. first additional a a I -- I with is with exposure cycles. efficacy said, the

a think I rate efficacy make call from So think a the hard would mature. data be really response an really I it's now right to standpoint, standpoint, not

have seen comment So is responses. we can all I

perspective. interested that from So these well we are course, that out as before in we're we seeing of encouraged data. put And

question. that answer I sorry, can't So, directly

Dane Leone

Yes.

to here line. comparable drug patients ask to helpful govitecan. of be on patients, like SN, which sounds you still you way, terms in It to these this need might exposure be of have cycles that keep XX the more sacituzumab me of let the So the ADC

idea study? showing rates. AE up plausibly, is the meaningfully ultimately clinically could you product this think you're different cohort, be that of for you for target the either you some hoping these to Do pick of have rates would some of thrombocytopenia, want an in comparison that the you're So on for profile go whatever key the what event table neutropenia, the of with

Raj Malik

Yes.

-- safety really the That's from following do we've right? I So right right the you beginning, as trial. been in mentioned, any what data,

that and remained with so relatively consistent patients put both additional have And the neutropenia for the we rates what the with actually been enrolled. out there diarrhea have

definitely consistent The change general as the from in potentially patients numbers beginning. will -- exposure with But from definitely increased absolutely You're and it with has right. with been well. just kind of more

it's febrile In are where terms including of hope neutropenia neutropenia. would and improvement, show we meaningful really AEs consequences what an its to the most

Of intriguing think, course, early are the are you is I label, warnings And diarrhea those the I I look the would sacituzumab really -- say. think finding, on at label. if two

So that's else we're following closely. something that

course, the early Of to speaks well, which the encouraged effect as effect on anemia of with we're of multi-lineage sort indicators here.

Dane Leone

now, for study? question XX -- Last you you'd enrolled have did me, to in you Did so the complete that do that enrollment? still the just XX expect you understand when I hit correctly, need target to enrollment

Raj Malik

hoping -- the potentially patients, of number the target. in in next and year. but have XX end we'll that required by That's of our We're but efficacy the set and even -- we're the safety of Yes. quarter said, the and I present the yes, talking as we'll second -- data the year approximately

Operator

we bring the while by stand Please Dane. question. you, next Thank

Okay.

is comes next open. Ed, H.C. Ed now line Wainwright. question from from your Our

Ed White

for Thanks morning. Good taking questions. my

third the diagnoses any the trend the had quarter is quarter Do you small and due have as for It you information to historical in goes? cancer? that be mentioned were So some down, cell diagnosis it far as for the -- lung could fourth seasonality. what of

Andrew Perry

patient is Yes, And would way we thanks, the through that it track say I claims. Ed.

for diagnoses. rather time to the patients technically really it's than on therapy going first So

So within a was August without month relatively can our flat it vary at platinum example, quarter. seasonality it's patients etoposide to within looking quarter, best be month-to-month. on and the yes, atezolizumab We or with -- going that And we track. launch for to-date

So be vary month-to-month. it can certainly

last last of also QX of we back QX growth contained highest there are show the where growth think around towards point. of particularly some in clearly, year, months periods be But But last QX year, some of end at at overall, Looking quarterly year our XX%. seasonality. then might that of QX in there

the in I've capability marketplace that discussed, improved to some a year, we're have with forward that of our and with new this believe looking we So tactics good QX. the we

Ed White

And were Andrew. two wanted down Thanks thoughts Okay. on we sequentially. two quarters I if get the to last can of a R&D for expenses expenses questions also quarters. SG&A couple were down fourth Jen. the the last of of just last know your the any quarter. -- each sequentially

Jen Moses

stats Ed. data just down like some bit sites down, little that say add going anymore. R&D as Hi, a pay everything and quarter, line, to in Yes, we're we're think readouts for not higher we on complete, because but wind would we're do I to But that expect to to Yes, having are that and we're patients next sure. studies there I just be as actually I these the up would wind coming not and having tends costs. be

to So those come down. continue costs will

SG&A, with line For in have, not changes pretty I what expect would it anticipating to we any there. stay major

Ed White

you Thanks, any give on Jen. us guidance can runway? And cash

Jen Moses

Sure.

a as the a to, alluded we sales guidance haven't are things, So light variability the the given pulled on was from down $XX more utilization that up think I sales Hercules, also of the XXXX, yet, continued before I and we in million based Andrew think couple just in quarter-over-quarter, of line. guidance we into seeing ramp had of which fact

not guidance although at us giving there. this time So that get do scenarios have to XXXX we

Ed White

you. I questions Thanks, Thank Jen. That's Okay. have. all the

Jack Bailey

Thanks, Ed.

Operator

Thank next you, the Please for standby Ed. question.

Anupam from JPM. comes question from next Our

open. Your line is

Malcolm Kuno

for on with hurdles of are of Kuno marketing Rama. getting key you're hearing pushback COSELA? the Malcolm the terms or for question. is Anupam this on that Board new prescribers taking some in Thanks Hi, What

Andrew Perry

extent We understanding over And has is actually myelosuppression of with and have which that is we've the in real in of is of world and which problem can first a with of of presented patients been terms extent now evidence promotion, incredible at consequences real true that's on real the really last thousands Yes, the thanks. the patients et reduction an world, of the with in cetera. our been so, of life. the hospitalizations, shows those immensely effectiveness because burden treatment. all, remain The conferences barriers same course, become of myelosuppression, way the or of year dealing which that chemotherapy it

that good feel organizations, have a a tell use. a get new perspective these into marketing processes next with is, we're part we do product from The to of So position many complex story. they consistent to in

usually appointments, because to cell to just move taking of whatever. do patients. benefit that trial going we with that And tougher that, in that or and finally, our that. the work the eligible see and patient available process EMR they down. those trial members that from means it so of certainly maybe all many from edition, because sure trial having persistent you an go patients. risk some It could aren't a edition, time, patient vacations extensive do small take conversations And staff of together, with, then make to And in getting seeing seasonal to involves a means process, patient can that stage formulary To Order because adoption those to have with Set wanting it of through adoption use was through a high just moving all have first to QX, are lot then through that and slow we time to to providers in efforts it all staff not

So we get there. have to out

have to efforts. peer-to-peer expand our We

our See live we're who world to and their energy with with speakers looking too. forward COSELA months efforts, real I was digital but with incredible it, We the bureau, for we've not experience digital live-to-live as from expanding our speaker speaker as their mentioned stories only have to -- forward our that And actually have before, that training. efforts. first really last room expand fantastic. sharing the our having the advocated made they strides over It in few peers

Malcolm Kuno

for that Thanks background. Great.

Operator

comes standby Thank And PacGrow. next question. from next our the David question for you. Please from Wedbush

is line Your now open.

David Nierengarten

Hey, questions. taking quick thanks for ones. the Two

was Trodelvy. -- neutropenia other after prophylax rates for are problems as were study? cycle a patients First, could of us was might it? with first in pre-treatment with have any SN continued to neutropenia, if think the allowed you be Thanks. you Is the what the might if of -- triple negative the quick then, know agents for who support Neulasta allowed whatever in I with or do you patients G-CSF remind there severe a what the in study other follow-up, Neulasta And

Raj Malik

and we so proportion that Raj. including trial. is SN in that supportive right factors of And and it recall to -- what Yes, to G-CSF, around. kind allowed was range. I'm Hey, on. you're received recall David, allowed I seem I growth so this care transfusions in also and the think trying I Yes,

of so that would proportion neutropenia, in a lower So in lower the something study, clearly the given with that's yes, our well following expect we trial. to rate are but as be combination we

David Nierengarten

your And any receive far did so G-CSF? patients Okay. study in it

Raj Malik

know, You Yes. that. not of I'm aware

Operator

next Thank standby our Please next Cowen And Company. question. you. our from and comes Troy, for question

Your is open. line

Troy Langford

all progress, taking again our for Hi Congrats and on everyone. thanks questions.

have maybe one for two I Raj then one just and CRC, for on Andrew. questions So

So these compare reduction for data COSELA what do you CRC? some can CRC think would excited? lot your of any already feel possibly you of and you how first Andrew of if penetrate a established all you on you centers? maybe And next market data like for opportunity those all at make you see to idea of the accounts quarter, And remind relationships the us in then just CRC, the level there? given neutropenia on expectations faster have you overlap have top Do much could do so, that the all in

Raj Malik

Hey, Troy, this is Raj.

way rate. in about have a this XX-odd-percent trial in staffs colorectal neutropenia FOLFOXIRI give data, reduction, So for is right? with we see Grade a Phase the THRIVE X to defined rate So X Yes, the I'll we go a first. context so the you obviously expect on a based just the and to

if going So be we And a significant trial and designed over to that's I the meet clinically show that. that, is statistically reduction think meaningful. to

that hope think know, that FOLFOXIRI you your and myelotoxicity. continuing really helps I the as I for So exciting is answer question that hurdle major would be because

going we're that, if upon to benefit believe able a to we that's be patients. So for improve

Andrew Perry

think in but so office, Troy, or overlap, will very really the significant within staffing I I'll do really, a the the Yes, there They'll particularly one. on see in often all types. where have community oncologists specialist chip tumor be multiple the comers. they'll community second Yes, and within be see that network will

well through is that academic as will to think center a to of our centers do little a able engage up in be different. we I with as medical community. think get treated CRC the affairs have But be the in organization to I to commercially them both And lot those folks.

I able the Also single is will terms thing this list our out be probably of be speed So of patients. the overlap uptake, more more the types? champions today of are on to biggest think use get to do COSELA wish you tumor want of when there. in my to there with there I going

do think early COSELA who multiple indication. that see more we some people so become in in by familiar I adoption the And with just having tumor will types

are us future and that So incredibly customers telling excited too. volume our our potential, deliver can't they're wait we to about

Troy Langford

Thanks Awesome. helps much color. so right. all the That All for a lot.

Jack Bailey

muted? you are Operator,

Operator

thank last Our -- you. My apologies.

comes question ROTH Tony, is from last Our open. your line Capital. from Tony

Tony Butler

data questions, Trodelvy, three -- I've very the triple just treatment the Thanks if half roughly go XX%. label patients Raj, interruptions, -- much. back from treatment to SN straight got or in which the breast -- you of brief to the cancer with Raj just in of math all, are Good negative of first lead morning. interruptions and and if XX% do we the

fifth to dose request I it Question XX%? some a That’s if to would only QX? increase in it occur? it face-to-face two we per And question say? your get you is type frame made same Is actually the as Are making the too increased? Thanks Is that then, have data center about much. five you're you or reduction in believe is, correctly. center is of would you that do of level very early per in to in contact. look have reference that you after Andrew, data? I've you it you inning If finally, trying may. QX having quarter-to-quarter sales surgery the reps do fact the expected to interruption. one I this correctly, characterized statements numbers on in basis? If patients, -- at the I'm run least a would've patients on there is why that the it surgeries -- when Or on the granular get at Has XX as

Raj Malik

this is Tony, Raj. Hey,

at I moment. but So the yes, ongoing something certainly delays, seen very think reductions encouraged to-date, by dose study, color mean, I I we're that is the is dose all provide closely. following Obviously think we're we've I what can

Andrew Perry

our Tony our it which so of over has -- chip I'll in are markedly engagements new XX% since gone introduced fantastic. sales the And team, face-to-face. we because seasonal voice before, off is is It on yes, we QX our face-to-face variations, bit limited to during mentioned I share of actually although saw as access in little interesting, stable Really but QX. those a remains customers

face-to-face during basically some to that the have companies to with been there. the we've discussions. our customers have there's means ability that get overall, very, all lends of period, -- and limited So customers substantive again But itself access pleased very to folks which to that that fact seasonality

any tracking setting, In don't in terms of our we and procedure of anything. data Raj can track but you, the last sure quite with question, was I'm I maybe kind not answer, commercial if surgical

Tony Butler

correct? in that I down that Is So but lung cell Am the fact you alluded to way? small cancers QX. the XX% were

Andrew Perry

Yes.

Tony Butler

I correctly hear would information surgery or something Did actually you had to surgery. that patients had all I that? it's track whether have these not diagnoses assume otherwise So about or

Andrew Perry

for Great, Actually it's for No. data great or atezolizumab. based platinum point. on clarification. the Thanks without so claims etoposide with

Tony Butler

Okay.

Andrew Perry

And with stage. is of of that in presence a of or extensive for without regimen extensive the diagnosis majority use the stage vast obviously

we how that's judge So that.

the tell marketplace, paid not accompany in We'll for many new us but basically procedures surgical a how it's would existing patients related the regimen. to to line that that. that it's So are claim

Operator

closing Jack for Tony. you, to like Thank now the to CEO, our remarks. turn it back would I -- Bailey to CEO over

Jack Bailey

Thank you, Operator.

as we'll all be well thank and Certainly, As updated touch. we today. stay always, Please joining keeping in forward for we progress. look you you to us

Operator

much. This call. so you now the Thank concludes

We disconnect line. will now the

G1 Therapeutics (GTHX) 2 Nov 222022 Q3 Earnings call transcript